^
    Back
    Association details:
    Biomarker:FGF19 overexpression
    Cancer:Hepatocellular Cancer
    Drug:Ibrance (palbociclib) (CDK4/6 inhibitor) +
    H3B-6527 (FGFR4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Research
    Title:

    H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma

    Excerpt:
    …these observations suggest that palbociclib combines well with H3B-6527 to enhance H3B-6527 efficacy in FGF19-overexpressing HCC models.
    DOI:
    10.1158/0008-5472.CAN-17-1865